# Quantitative Oncology Research Program

> **NIH NIH P30** · OREGON HEALTH & SCIENCE UNIVERSITY · 2024 · $59,918

## Abstract

PROJECT SUMMARY: Quantitative Oncology Research Program
Paul Spellman, Ph.D., and Laura Heiser, Ph.D., Program Co-Leaders
The Quantitative Oncology (QO) Program is a multi-disciplinary research program formed to facilitate the
development of advanced technologies for cancer measurements and treatment, deeply characterize the
molecular and phenotypic states of cancers, and apply computational models to predict cancer behaviors and
outcomes. Program members develop and apply advances in ‘omic and imaging technologies, coupled with big
data analytics to enable quantitative understanding of the behavior of cancerous cells and tissues as they evolve,
respond to therapy, and interact with their microenvironments. This collaborative research program is organized
around three themes: 1) Technology Development (imaging, devices, and single-cell analyses), 2) Omics and
Characterization (comprehensive assessment of cancer cells and tissues), and 3) Systems Biology
(properties of cancer-related molecular networks, the molecular and cellular phenotypes they regulate, and their
evolution and adaptation during cancer development and treatment). QO research and innovation provides a
strong foundation for advances in the strategic priorities of the Knight Cancer Institute (KCI), Precision Early
Detection and Precision Oncology. The expertise in QO is essential to the development and deployment of tools
for comprehensive tumor analytics and the computational methodologies critical to detect early cancers, discover
predictors of response/resistance to therapy, and drive novel combination therapy approaches. The QO Program
is co-led by Paul Spellman, Ph.D., an expert in the application of translational cancer genomics to cancer
detection and classification, and Laura Heiser, Ph.D., an expert in cancer systems biology and imaging
technologies. The QO Program has 44 members drawn from six basic science departments and four clinical
departments in the OHSU School of Medicine, and Pacific Northwest National Laboratory. Total cancer-related
direct cost funding as of December 31, 2020 was $6,589,354, with peer-reviewed funding of $5,904,119, and
$3,469,050 or 59% of peer-reviewed funding coming from the NCI. The discoveries made in this program have
resulted in 507 publications, of which 27% are intra-programmatic collaborations, 48% are inter-programmatic
collaborations, and 47% are inter-institutional. Program members have leading roles in many major NCI
initiatives, including the Cancer Systems Biology Centers, the Genome Data Analysis Network and Human
Tumor Atlas Network, and the Biden Cancer Moonshot grant, Evaluation of Population Based Testing for HBOC
and Lynch Syndromes. Program members have leadership roles in data science initiatives including Galaxy and
AnVIL, the NHGRI’s Genomic Data Science Analysis, Visualization, and Informatics Lab-space.

## Key facts

- **NIH application ID:** 10891360
- **Project number:** 5P30CA069533-26
- **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY
- **Principal Investigator:** PAUL T. SPELLMAN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $59,918
- **Award type:** 5
- **Project period:** 1997-08-01 → 2027-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10891360

## Citation

> US National Institutes of Health, RePORTER application 10891360, Quantitative Oncology Research Program (5P30CA069533-26). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10891360. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*